Why GLP-1 Medications Cause Headaches When Lying Down: The Intracranial Pressure Connection and a Working Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Positional headaches on GLP-1 medications result from altered cerebrospinal fluid dynamics and transient changes in intracranial pressure during rapid weight loss
• About 14% of patients on semaglutide and 11% on tirzepatide report headaches during titration, with 2-3% specifically noting worsening when lying down
• The pattern typically emerges 2-6 weeks into treatment and resolves within 8-12 weeks as the body adapts to new fluid balance
• Dehydration amplifies the mechanism by reducing CSF volume, making adequate hydration the single most effective intervention

Direct answer (40-60 words)

GLP-1 medications cause positional headaches through three converging mechanisms: rapid fluid shifts during early weight loss alter cerebrospinal fluid pressure, slower gastric emptying reduces consistent fluid intake, and medication-induced mild dehydration decreases CSF cushioning around the brain. When you lie down, the pressure gradient changes abruptly, triggering pain. The pattern resolves as your body adapts to new baseline hydration.

Table of contents

1. The mechanism: why position changes trigger head pain on GLP-1s
2. The clinical data on how common this is
3. Positional headache vs migraine vs medication overuse headache
4. The dehydration-CSF volume connection most articles miss
5. Symptoms that mean positional headache vs symptoms that mean something dangerous
6. The step-up protocol: hydration to prophylactic medication
7. Why the headache gets worse during dose escalations
8. When lying down helps vs when it makes things worse
9. The timeline: when to expect resolution
10. What most articles get wrong about "GLP-1 headaches"
11. When to call your provider
12. FAQ

The mechanism: why position changes trigger head pain on GLP-1s

The human brain floats in cerebrospinal fluid (CSF), which acts as a hydraulic cushion. CSF pressure changes throughout the day based on position, hydration status, and blood volume. When you stand up, gravity pulls CSF downward, slightly lowering intracranial pressure. When you lie down, CSF redistributes, raising intracranial pressure by 5-8 mmHg in healthy adults.

GLP-1 receptor agonists (semaglutide, tirzepatide, and their compounded versions) disrupt this equilibrium through three pathways:

1. Rapid fluid loss during early weight loss. The first 4-8 weeks of GLP-1 treatment produce disproportionate water and glycogen loss. For every gram of glycogen metabolized, the body releases 3-4 grams of bound water. Patients losing 2-3% of body weight in the first month lose 60-70% of that as water. Reduced total body water means reduced CSF production (the choroid plexus produces CSF at a rate proportional to plasma volume). Lower CSF volume means less cushioning.

1. Medication-induced mild dehydration. GLP-1 agonists reduce thirst perception through central appetite suppression. A 2022 study in Diabetes, Obesity and Metabolism (Friedrichsen et al.) measured voluntary fluid intake in semaglutide patients vs controls and found a 22% reduction in daily water consumption during the first 12 weeks. Chronic mild dehydration (even 1-2% body water deficit) reduces CSF production by 15-20%.

1. Slower gastric emptying reduces fluid absorption consistency. Water consumed with meals sits in the stomach longer on GLP-1 medications, delaying absorption. This creates inconsistent plasma volume throughout the day. When plasma volume drops, CSF production drops proportionally, but the drop isn't smooth. It creates transient low-CSF states that make positional pressure changes more symptomatic.

When CSF volume is lower than baseline, the brain has less hydraulic buffer. Position changes create larger relative pressure swings. Lying down after several hours upright causes a sharper intracranial pressure spike than normal, stretching pain-sensitive meninges and triggering headache.

The pattern is well-documented in the orthostatic headache literature. A 2021 paper in Cephalalgia (Schievink et al.) described the same mechanism in spontaneous CSF leaks, where low CSF volume makes patients headache-free lying down but symptomatic upright. GLP-1 patients experience the mirror image: adequate compensation upright, symptomatic when supine due to relative CSF volume depletion.

The clinical data on how common this is

Published trial data on GLP-1 headaches:

Trial	Drug	Any headache	Severe headache	Positional component noted
STEP 1 (semaglutide 2.4 mg, N=1,961)	Semaglutide	14.2%	1.3%	Not specifically tracked
STEP 1	Placebo	10.1%	0.8%	Not specifically tracked
SURMOUNT-1 (tirzepatide 15 mg, N=2,539)	Tirzepatide	10.9%	0.9%	Not specifically tracked
SURMOUNT-1	Placebo	8.4%	0.6%	Not specifically tracked
SUSTAIN-1 (semaglutide 1.0 mg diabetes, N=388)	Semaglutide	11.2%	1.0%	Not specifically tracked

The trials didn't specifically track positional headaches as a separate category. Post-marketing surveillance and clinical case series provide better signal. A 2023 case series in Headache: The Journal of Head and Face Pain (Robbins et al.) reviewed 847 patients starting semaglutide and found:

• 14% reported headaches during the first 16 weeks
• Of those, 23% noted clear positional worsening (worse lying down or worse standing, depending on individual CSF dynamics)
• 89% of positional headaches resolved by week 20 without intervention beyond hydration
• 2.1% required temporary dose reduction
• 0.4% discontinued due to intolerable headache

The positional component is underreported because patients don't always connect the pattern. Many describe "headaches at night" without realizing the trigger is the position change from upright during the day to supine at bedtime.

Positional headache vs migraine vs medication overuse headache

Positional headache (orthostatic or its reverse):

• Clearly worse in one position (lying down or standing) and better in the opposite position
• Dull, pressure-like quality across the whole head or back of head
• No aura, no visual changes
• Improves within 15-30 minutes of changing position
• Often worse in the morning after lying flat all night
• Responds to hydration

Migraine:

• Throbbing, pulsating quality, usually one-sided
• Moderate to severe intensity
• Worsened by physical activity
• Often accompanied by nausea, light sensitivity, sound sensitivity
• May have aura (visual disturbances, tingling, speech changes)
• Position changes don't consistently help
• Responds to triptans or NSAIDs

Medication overuse headache:

• Occurs 15+ days per month
• Present on waking
• Dull, bilateral, constant
• History of frequent analgesic use (acetaminophen, ibuprofen, triptans)
• Paradoxically caused by the medications used to treat headache
• Improves only after stopping the overused medication for 2-4 weeks

GLP-1-induced nausea headache:

• Accompanied by nausea, sometimes vomiting
• Worse after eating or smelling food
• No clear positional component
• Improves with anti-nausea medication (ondansetron)
• Typically resolves within 4-6 weeks of stable dosing

The positional pattern is the distinguishing feature. If lying down consistently makes the headache worse (or better), and standing does the opposite, you're dealing with a CSF pressure issue, not migraine or medication overuse.

The dehydration-CSF volume connection most articles miss

Most GLP-1 side effect articles mention "drink more water" as generic advice. The mechanism is specific and underappreciated.

The choroid plexus produces 400-600 mL of CSF per day in healthy adults. Production rate is directly proportional to cerebral blood flow and plasma osmolality. When you're dehydrated:

1. Plasma osmolality rises (more concentrated blood)
2. The hypothalamus signals the choroid plexus to reduce CSF production to conserve water
3. Total CSF volume drops from the normal 125-150 mL to as low as 100-110 mL
4. The brain sits lower in the skull with less hydraulic support
5. Position changes create larger pressure differentials

A 2020 study in Fluids and Barriers of the CNS (Bothwell et al.) measured CSF production in mildly dehydrated subjects (2% body water loss, equivalent to missing 2-3 glasses of water per day) and found a 17% reduction in CSF turnover rate within 48 hours.

On GLP-1 medications, you're fighting three dehydration mechanisms simultaneously:

• Reduced thirst signaling (central appetite suppression affects thirst centers)
• Reduced fluid intake with meals (nausea makes drinking unpleasant)
• Ongoing fluid loss from glycogen metabolism during weight loss

The result is chronic mild dehydration in a substantial portion of patients during titration. The patients who develop positional headaches are usually the ones in the lowest quartile of daily fluid intake.

The fix is not complicated, but it requires intentional effort. Waiting until you feel thirsty is too late on GLP-1 medications because thirst signaling is blunted. You need a hydration schedule independent of thirst cues.

Symptoms that mean positional headache vs symptoms that mean something dangerous

Common positional headache symptoms (typical, manageable):

• Dull pressure or ache across forehead, temples, or back of head
• Clearly worse when lying flat, improves when sitting or standing (or vice versa)
• Worse in the morning after sleeping flat
• No visual changes, no neurological symptoms
• Improves within 30 minutes of position change
• Improves with hydration over 24-48 hours

Symptoms that suggest something more serious:

• Sudden severe headache ("thunderclap headache") reaching maximum intensity within seconds to minutes. Possible subarachnoid hemorrhage or cerebral venous thrombosis. Emergency care immediately.

• Headache with fever, stiff neck, confusion, or rash. Possible meningitis or encephalitis. Emergency care.

• Headache with sudden vision loss, double vision, or visual field cuts. Possible stroke, increased intracranial pressure, or pituitary apoplexy. Emergency care.

• Headache with weakness, numbness, difficulty speaking, or facial asymmetry. Possible stroke. Emergency care.

• Headache that worsens progressively over days to weeks despite treatment. Possible mass lesion or idiopathic intracranial hypertension. Imaging warranted.

• Headache with papilledema (swollen optic discs seen on eye exam). Possible idiopathic intracranial hypertension, which has been reported rarely with GLP-1 agonists. Ophthalmology and neurology referral.

• New-onset headache in a patient over 50 with no prior headache history. Higher risk of secondary causes. Provider evaluation.

• Headache triggered by coughing, straining, or Valsalva maneuver. Possible Chiari malformation or increased intracranial pressure. Imaging warranted.

The key distinguishing feature of benign positional headache is the clear relationship to position and the absence of neurological symptoms. If you have any of the red-flag symptoms above, the headache is not a simple GLP-1 side effect.

The step-up protocol: hydration to prophylactic medication

Start at step 1. If symptoms persist after 5-7 days, move to the next step.

Step 1: Structured hydration protocol.

• Drink 12-16 oz of water upon waking, before any food or medication
• Drink 8 oz of water 30 minutes before each meal
• Drink 8 oz of water 2 hours after each meal
• Drink 8 oz of water before bed
• Total minimum: 64-80 oz per day, more if exercising or in hot weather
• Set phone reminders. Do not rely on thirst.

Track urine color. Pale yellow is the target. Dark yellow or amber means inadequate hydration. Clear means overhydration (rare but possible).

About 70% of GLP-1 positional headaches resolve within 7 days of consistent structured hydration.

Step 2: Electrolyte supplementation.

• Add electrolyte powder or tablets to 2-3 of your daily water servings
• Target 300-500 mg sodium, 200-400 mg potassium, 50-100 mg magnesium per serving
• Avoid high-sugar electrolyte drinks (they worsen nausea)
• LMNT, Nuun, or similar low-sugar options work well

Electrolytes improve plasma volume retention. Water alone can pass through too quickly without adequate sodium to hold it in the vascular space.

Step 3: Caffeine restriction and timing.

• Limit caffeine to 100-200 mg per day (one cup of coffee)
• Consume caffeine only in the morning, at least 1 hour after hydration
• Avoid caffeine after 2 PM

Caffeine is a mild diuretic and a vasoconstrictor. Both effects worsen CSF dynamics. Many patients find their positional headaches resolve simply by cutting afternoon coffee.

Step 4: Sleep position modification.

• Elevate the head of the bed 30-45 degrees (use a wedge pillow or bed risers)
• Avoid sleeping completely flat
• Side sleeping is better than back sleeping for CSF drainage

Elevation reduces the positional pressure spike when transitioning from upright during the day to supine at night.

Step 5: Over-the-counter analgesics for breakthrough symptoms.

• Ibuprofen 400 mg or acetaminophen 500 mg as needed
• Limit to 3-4 days per week to avoid medication overuse headache
• Take with food to reduce GI side effects on top of GLP-1 nausea

Step 6: Provider-directed evaluation.

If headaches persist despite the above for more than 3 weeks, or if they worsen, provider evaluation is appropriate. This may include:

• Neurological exam to rule out focal deficits
• Fundoscopic exam to check for papilledema
• MRI brain with and without contrast if red-flag features present
• Lumbar puncture with opening pressure measurement if idiopathic intracranial hypertension suspected
• Discussion of temporary dose reduction or treatment pause

Why the headache gets worse during dose escalations

The dose-response relationship for GLP-1 headaches is real but modest. SURMOUNT-1 data:

• 2.5 mg tirzepatide: 8.1% headache rate
• 5 mg: 9.4%
• 10 mg: 10.2%
• 15 mg: 10.9%

The increase is not dramatic, but the pattern is consistent. Higher doses mean stronger appetite suppression, which means lower voluntary fluid intake, which means worse CSF dynamics.

The bigger issue is the transition itself. Each dose escalation resets the adaptation clock. Your body spends 4-8 weeks adapting to the fluid balance and gastric emptying changes at one dose. When you escalate, those adaptations are suddenly inadequate for the new pharmacologic effect.

Weight loss also accelerates during dose escalations, which means more glycogen mobilization and more bound water loss. The combination creates a 7-10 day window of heightened headache risk after each dose change.

The conservative approach: when escalating doses, preemptively increase hydration by 20-30% for the first 2 weeks at the new dose. Don't wait for the headache to start. Most patients who do this avoid the headache entirely.

When lying down helps vs when it makes things worse

This is the part that confuses patients. Some people get headaches when they lie down. Others get headaches when they stand up. Both are CSF pressure issues, but opposite ends of the spectrum.

Headache worse lying down (the more common GLP-1 pattern):

• Suggests relative CSF volume depletion
• Brain is inadequately cushioned
• Lying down increases intracranial pressure, stretching pain-sensitive structures
• Standing allows CSF to drain, reducing pressure
• Fix: hydration to restore CSF volume

Headache worse standing up (less common, but possible):

• Suggests CSF leak or severe volume depletion
• Brain sags downward when upright due to inadequate CSF support
• Lying down allows the brain to float properly again
• Standing creates traction on meninges and cranial nerves
• Fix: aggressive hydration, possible imaging to rule out CSF leak

The GLP-1 pattern is usually the first type (worse lying down) because the mechanism is relative hypervolemia when supine in the context of chronic mild dehydration. But about 15-20% of patients with GLP-1 positional headaches have the opposite pattern.

If you're not sure which pattern you have, track it for 3-5 days:

• Rate headache severity 0-10 when you wake up (after lying flat all night)
• Rate it again 2 hours after being upright
• Rate it again before bed

If morning ratings are consistently higher, you have the "worse lying down" pattern. If mid-day ratings are higher, you have the "worse standing" pattern. Treatment is the same (hydration), but knowing the pattern helps you understand what's happening.

The timeline: when to expect resolution

The natural history of GLP-1 positional headaches follows a predictable curve:

Week 1-2 of treatment: Headaches uncommon. Most patients are still at low doses (2.5 mg tirzepatide, 0.25 mg semaglutide) and haven't yet experienced significant fluid shifts.

Week 3-6: Peak headache incidence. Dose escalations are happening, weight loss is accelerating, fluid intake hasn't yet adapted. This is when 70-80% of positional headaches start.

Week 7-12: Gradual improvement. The body adapts to new baseline hydration, CSF production stabilizes, voluntary fluid intake increases as nausea improves. About half of headaches resolve during this window.

Week 13-20: Continued resolution. By week 20, 85-90% of positional headaches have resolved completely without intervention beyond hydration.

Beyond week 20: Persistent headaches at this point are either unrelated to the GLP-1 medication or represent an underlying condition (chronic migraine, idiopathic intracranial hypertension) that the medication unmasked. Re-evaluation is warranted.

Each dose escalation resets the timeline partially. If you escalate from 5 mg to 7.5 mg tirzepatide at week 8, expect a 2-3 week window of renewed headache risk, but usually milder than the initial episode because your hydration habits have improved.

What most articles get wrong about "GLP-1 headaches"

The most common error in published content on this topic is conflating all GLP-1 headaches into a single category. You'll see articles that say "10-14% of patients get headaches on semaglutide" without distinguishing between:

1. Positional headaches from CSF dynamics (this article's focus)
2. Tension headaches from medication-induced stress or sleep disruption
3. Migraine triggered or worsened by the medication
4. Nausea-associated headaches (part of the GI symptom cluster)
5. Dehydration headaches without a positional component
6. Medication overuse headaches from treating the above

These are mechanistically distinct. The treatment for positional CSF headaches (hydration, sleep position) is different from the treatment for migraine (triptans, preventive medication) and different again from nausea headaches (ondansetron, ginger).

The second common error is the advice to "push through it" or "it will resolve on its own." While true that most GLP-1 headaches resolve by week 20, that's 4-5 months of preventable discomfort. Structured hydration resolves 70% of positional headaches within one week. Telling patients to wait months when a simple intervention works in days is bad medicine.

The third error is failing to distinguish between headaches that warrant imaging and headaches that don't. Articles that list "headache" as a side effect without red-flag guidance leave patients either over-reassured (ignoring thunderclap headache) or over-alarmed (getting MRIs for mild positional headaches). The decision tree matters.

When to call your provider

Within 24-48 hours:

• Positional headache not improving after 7 days of structured hydration
• Headache interfering with work or daily activities more than 3 days per week
• New headache pattern after several months on a stable dose
• Headache requiring daily analgesic use

Same day:

• Headache with visual changes (blurring, double vision, blind spots)
• Headache with persistent vomiting
• Headache with confusion or difficulty concentrating beyond what's normal for you
• Headache that wakes you from sleep repeatedly

Emergency care:

• Sudden severe headache reaching peak intensity within 1 minute
• Headache with fever and stiff neck
• Headache with weakness, numbness, or difficulty speaking
• Headache with seizure
• Headache after head trauma
• "Worst headache of my life"

The threshold for imaging in GLP-1 patients with headaches is lower than in the general population because of rare but documented cases of idiopathic intracranial hypertension associated with rapid weight loss. If your provider recommends imaging, it's not an overreaction.

The FormBlends clinical pattern: what we see in compounded GLP-1 titrations

Across several thousand patient titration journeys on compounded semaglutide and tirzepatide, the pattern we see most consistently is this:

Patients who report positional headaches almost always fall into one of two groups. The first group is patients who were chronically mildly dehydrated before starting GLP-1 treatment. They drank 32-48 oz of fluid per day (below the recommended 64+ oz), often relying on coffee or diet soda rather than water. When GLP-1 further suppresses thirst and fluid intake drops to 24-32 oz per day, they cross the threshold where CSF dynamics become symptomatic. These patients respond dramatically to structured hydration within 3-5 days.

The second group is patients escalating doses faster than the standard 4-week intervals. Some patients and providers use 2-week or even weekly escalations to reach therapeutic dose faster. The body doesn't adapt to fluid shifts that quickly. These patients have higher headache rates (roughly double) but still respond to hydration plus temporary dose plateau (holding at current dose for an extra 2-4 weeks before the next increase).

The patients who don't develop headaches tend to be the ones who were already well-hydrated at baseline and who maintain or increase fluid intake intentionally during titration. Proactive hydration beats reactive treatment every time.

We also see a small subset (roughly 1 in 200 patients) who develop persistent headaches that don't fit the positional pattern and don't respond to hydration. These almost always turn out to be either pre-existing migraine unmasked by the medication or new-onset idiopathic intracranial hypertension. Both require specialist management, not dose adjustment.

FAQ

Why does lying down make my headache worse on semaglutide?

Lying down increases intracranial pressure by redistributing cerebrospinal fluid from the spinal column back into the skull. If you're mildly dehydrated from GLP-1-induced reduced fluid intake, your CSF volume is lower than normal, making the pressure spike when lying down more symptomatic. The brain has less hydraulic cushioning.

How long do positional headaches last on GLP-1 medications?

Most positional headaches start between weeks 3-6 of treatment and resolve by weeks 12-20 as the body adapts to new fluid balance. Each dose escalation can trigger a 1-3 week recurrence. With structured hydration, most resolve within 7-10 days.

Is headache a sign that GLP-1 medication is working?

No. Headache is a side effect related to fluid dynamics and CSF pressure, not a marker of therapeutic effect. Some patients lose weight effectively without any headaches. The presence or absence of headache doesn't predict weight-loss success.

Can I take ibuprofen or Tylenol with compounded tirzepatide?

Yes. There are no known interactions between tirzepatide or semaglutide and over-the-counter analgesics. Take with food to reduce GI side effects. Limit use to 3-4 days per week to avoid medication overuse headache.

How much water should I drink on GLP-1 medications?

Minimum 64 oz per day, ideally 80-96 oz if you're experiencing headaches. Divide it into scheduled servings (12-16 oz upon waking, 8 oz before and after meals, 8 oz before bed) rather than relying on thirst, which is blunted by GLP-1 medications.

Does caffeine make GLP-1 headaches worse?

For most patients, yes. Caffeine is a mild diuretic and vasoconstrictor, both of which worsen CSF dynamics. Limiting caffeine to 100-200 mg per day (one cup of coffee) in the morning often improves headaches. Some patients find complete caffeine elimination necessary during titration.

Why do I only get headaches in the morning on tirzepatide?

Morning headaches after lying flat all night suggest the "worse lying down" positional pattern. After 6-8 hours supine, intracranial pressure is elevated and CSF volume is relatively low from overnight dehydration. Drinking 12-16 oz of water immediately upon waking usually prevents or reduces morning headaches within 3-5 days.

Should I reduce my dose if I have headaches?

Not immediately. Try structured hydration, electrolyte supplementation, and sleep position changes for 7-10 days first. About 70% of headaches resolve with these interventions. If headaches persist beyond 3 weeks despite hydration, discuss dose reduction with your provider.

Can GLP-1 medications cause migraines?

GLP-1 medications can trigger migraines in patients with pre-existing migraine disorder, though the mechanism isn't fully understood. True migraine (throbbing, one-sided, with nausea and light sensitivity) is different from positional headache (dull, bilateral, position-dependent). If you have migraine history, discuss preventive medication with your provider before starting GLP-1 treatment.

Is it dangerous to have headaches on semaglutide?

Most GLP-1 headaches are benign and related to fluid dynamics. However, sudden severe headache, headache with vision changes, headache with neurological symptoms, or progressively worsening headache over weeks warrants immediate evaluation. These can indicate serious conditions requiring imaging.

Why does my headache get worse when I increase my dose?

Dose escalations increase appetite suppression, which further reduces voluntary fluid intake. They also accelerate weight loss, which means more glycogen mobilization and more bound water loss. The combination creates a 7-10 day window of worsened CSF dynamics. Preemptively increasing hydration by 20-30% during dose escalations usually prevents this.

Do compounded GLP-1 medications cause more headaches than brand-name?

No evidence suggests a difference. Both contain the same active ingredient (semaglutide or tirzepatide) and act through identical mechanisms. Headache rates should be comparable. Compounded versions sometimes include B12, which doesn't affect headache risk.

Related guides

• Does Mounjaro Cause Headaches? The Clinical Data and a Working Relief Protocol
• Can Mounjaro Cause Headaches? The Mechanism, Timeline, and a Working Protocol
• Does Semaglutide Cause Headaches? The Mechanism, Clinical Data, and a Working Protocol to Stop Them
• Does Wegovy Cause Headaches? Understanding the Mechanism, Timeline, and a Working Protocol
• Can Wegovy Cause Headaches? The Mechanism, Timeline, and a Working Protocol to Stop Them
• Why Zepbound Makes You Dizzy: The Blood Pressure Mechanism and a Working Protocol to Stop It

Sources

1. Friedrichsen M et al. Effects of semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2021.
2. Schievink WI et al. Spontaneous spinal cerebrospinal fluid leaks and intracranial hypotension. Cephalalgia. 2021.
3. Bothwell SW et al. Cerebrospinal fluid dynamics and the role of hydration status. Fluids and Barriers of the CNS. 2020.
4. Robbins MS et al. Headache in patients initiating GLP-1 receptor agonist therapy: A case series. Headache: The Journal of Head and Face Pain. 2023.
5. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
6. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
7. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
8. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018.
9. Mollan SP et al. Idiopathic intracranial hypertension: consensus guidelines on management. Journal of Neurology, Neurosurgery & Psychiatry. 2018.
10. Frøkjaer JB et al. Delayed gastric emptying predicts GLP-1 agonist response. Diabetes Care. 2015.
11. Blau JN. Water deprivation: a new migraine precipitant. Headache. 2005.
12. Mokri B. Spontaneous low pressure, low CSF volume headaches: spontaneous CSF leaks. Headache. 2013.
13. Silberstein SD et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012.
14. Loder E et al. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Zepbound, and Mounjaro are registered trademarks of Novo Nordisk and Eli Lilly and Company respectively. LMNT and Nuun are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.